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OPENING SESSION
Joseph Bick*, MD, Chief Medical Officer, California
Medical Facility, Calif. Department of Corrections
United Nations Special Envoy on HIV/AIDS in
Africa Stephen H. Lewis discussed the current
state of the HIV epidemic.
Worldwide it is estimated
that 10 million women
aged 15-24 years old are
HIV-infected, and six mil-
lion persons need anti-
retroviral treatment (ART)
based upon a CD4 count
of less than 200/mm³. An
estimated four million
Africans have a CD4 count
of less than 200/mm³; less
than 3% are receiving ART.  Worldwide, there
are an estimated 14,000 new infections each day
and three million HIV-related deaths per year.
Furthermore, the HIV epidemic has resulted in
millions of orphaned children.
Mr. Lewis detailed the World Health
Organization's "three by five" initiative, intended
to bring ART to three million people in Africa by
2005. Even if these goals are met, only half of
those who need ART will receive it.
Mr. Lewis questioned why "We have all of the
money needed to fight the war on terrorism, why
not to fight (the terror) of AIDS?"  He said,  "I beg
you to enter the fray" and "if morality is found
lacking in the actions of government, let it be
found in the advocacy of its citizens."
Mr. Lewis lamented the high number of women
who are being infected within "monogamous"
relationships by husbands who have sexual
partners outside of marriage. Worldwide, most
women are not empowered to insist upon con-
dom use or choose not to use them because
they interfere with conception.  
Without an effective vaccine or resources to pur-
chase ART, there is an urgent need for the devel-
opment of effective microbicides.   
Robin Shattock of St Georges Hospital and
Medical School in London, further elucidated this
topic in a presentation in which he described
how a marginally effective microbicide that is
used only half of the time could lead to a signifi-
cant decline in new infections. A useful product
would be active against a
wide range of HIV isolates,
non-toxic, active when
exposed to body fluids,
effective in both the vagina
and the rectum, inexpen-
sive, easy to manufacture,
stable in a variety of cli-
mates, and available with-
out prescription.    
In a symposium on the
global response to AIDS, some successes were
reported. Gavin Churchyard, MD, Director of
Aurum Health Research in South Africa
described a program in which gold mining com-
panies encourage voluntary testing of their
employees and provide treatment to those who
are found to be HIV-infected. This program has
led to ART adherence rates of over 90%, and
has resulted in a decrease in missed days of
work due to illness. Educating businesses to rec-
ognize the financial benefit of providing HIV
treatment to their workers may make it possible
for many persons to access care that they could
not otherwise afford. Anupong Chitwarakorn, MD
of the Ministry of Public Health in Thailand also
described targeted efforts in that country that
have led to an 80% decrease in the rate of new
infections between 1993 and 2003.  
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Update From the 11th Conference On
Retroviruses and Opportunistic Infections (CROI)
Held In San Francisco February 8-11 2004: First of Two Parts
“Worldwide, most women are
not empowered to insist upon
condom use or choose not to
use them because they 
interfere with conception.”
Metabolic complications of HIV and its ther-
apies have emerged as a major concern to
persons living with HIV infection and to their
health care providers.  The impact of com-
plications such as dyslipidemia, body shape
change and disorders of glucose metabo-
lism on HIV management may be evident in
both the surge in the use of atazanavir, a
protease inhibitor without significant effects
on lipids or glucose metabolism, and the
increasing prescription of lipid-lowering
drugs. At the 11th CROI, epidemiologic data
and a smattering of treatment trials regard-
ing metabolic issues were presented.
If the increased use of statins and fibrates
among HIV-infected patients is any indica-
tion, lipid abnormalities are becoming a fre-
quent complication of HIV therapy.  A fasci-
nating study recently published by Riddler
and colleagues in The Journal of the
American Medical Association suggests that
HIV infection itself causes declines in total
and LDL cholesterol and that these are
reversed by potent HIV therapy.  However, it
is also known that certain antiretrovirals can
increase lipid levels even among HIV-unin-
fected volunteers. Therefore, what contribu-
tion HIV therapy makes to overall cardiovas-
cular disease (CVD) risk is a subject of a
debate fueled by data both supporting and
refuting a role for HAART in CVD develop-
ment.  What is clear, however, is that not all
antiretrovirals affect the determinants of
CVD risk equally.  
This point was somewhat illustrated by data
from a substudy of AIDS Clinical Trials
Group study A384, a large treatment naïve
trial comparing efavirenz with nelfinavir
when combined with either ZDV+3TC or
d4T+ddI. While efavirenz led to greater
increases in HDL (probably a favorable out-
come), total cholesterol rose equally among
those receiving efavirenz and those
assigned nelfinavir. This finding supports
previous work demonstrating that nelfinavir
is less offensive to lipids than some of its sis-
ter protease inhibitors. There was a trend
toward d4T+ddI being worse, lipid-wise,
than ZDV+3TC. It should be noted that all
the analyses presented to date use an
intent-to-treat approach. Given that there
were more adverse events among those
receiving d4T+ddI and more virologic fail-
ures leading to treatment switches among
those assigned nelfinavir, the relationship
between actual exposure to these agents
and adverse metabolic events has yet to be
made clear.
The effect of HAART on other influences of
CVD such as hypertension and diabetes has
also been scrutinized.  Researchers from a
large consortium of European and North
American sites examined the prevalence
and incidence of hypertension among over
16,000 HIV-infected patients followed
prospectively in the D:A:D Study. Over a
median 1.5 years of follow-up, there was no
effect of HAART or time on HAART on the
prevalence of hypertension at entry or the
change in blood pressure during study fol-
low-up.  Factors associated with elevated
blood pressure were male gender, age,
baseline blood pressure and high body
mass index. Longer-term study is planned.  
The last National Cholesterol Education
Program (NCEP) guidelines emphasized
the role of diabetes in CVD, considering the
presence of this disorder equivalent to hav-
ing established CVD when setting goals for
lipid-lowering therapy. Previous reports have
suggested an increased prevalence of dia-
betes and pre-diabetic conditions among
HIV-infected persons. To assess the preva-
lence and incidence of glucose disorders as
well as the potential contribution of HAART,
investigators from the Multicenter AIDS
Cohort Study (MACS) examined 1,107 men
participating in the study from mid 1999 to
late 2002.  Of the 1,107 men , 563 were HIV-
negative and 544 were HIV-infected (423 on
HAART).  Hyperglycemia (pre-diabetes and
diabetes) was defined as fasting plasma glu-
cose >110 mg/dL, use of anti-diabetic med-
ication, or self-reported diagnosis of dia-
betes. Diabetes itself was defined as a FPG
>126 mg/dL, use of anti-diabetic medication,
or self-reported diagnosis of diabetes. Of
HIV-infected men on HAART, 14% had dia-
betes at baseline compared with 5% in the
HIV-negative group (odds ratio = 4.4; 95%
confidence interval [CI]: 2.6, 7.4).  
Among the cohort, 618 men had a FPG
<105 mg/dL, no history of diabetes, and no
use of anti-diabetic medication at baseline.
Incident hyperglycemia developed in 79/618
(13%) during 1,054 person-years yielding an
overall rate of 7.5 cases per 100 person-
years. Incident diabetes was detected in 38
during 1,088 person-years, yielding an over-
all rate of 3.5 cases per 100 person-years.
After adjustment for age and BMI, the haz-
ard of pre-diabetes or diabetes among those
on HAART was 1.8 times that of the HIV-
n gative group, and the hazard of diabetes
among the HAART group was 3.1 times that
of the HIV-negative group. Exposure to a
HAART regimen including a PI, d4T or
efavirenz were each significantly associated
with a higher rate of developing pre-diabetes
or diabetes compared to the HIV-negative
group. These robust data indicate that at
least in men, HAART is associated with risk
of diabetes.  Whether reduced reliance on
d4T and the older PIs will reduce the inci-
dence of diabetes among HIV-infected per-
sons receiving HAART will require further
follow-up.
In addition to lipid and glucose disorders,
body shape changes accompanying anti-
retroviral therapy are a challenge to patients
and their clinicians. Certainly, in correctional
settings where confidentiality is more chal-
lenging, the facial and limb fat loss that is
the hallmark of HIV-associated morphologic
changes can be a tell tale sign of HIV infec-
tion. Further, the redistribution of fat
observed in HIV-infected individuals, central
obesity and peripheral fat wasting, has been
associated with the metabolic syndrome and
heightened risk for CVD.  In addition, disfig-
uring body shape changes can reduce self-
esteem and threaten antiretroviral adher-
ence. To date, the only intervention to
improve peripheral lipoatrophy to any signif-
icant degree has been the replacement of
stavudine (d4T, Zerit) and, to a lesser extent
zidovudine (ZDV, Retrovir), with abacavir
(ABC, Ziagen).  Unfortunately, the increase
in limb fat following d4T discontinuation has
been modest and slow to be appreciated.  
A study from Australia aimed to determine if
the PPAR-gamma agonist, rosiglitazone,
could reverse fat wasting in HIV-associated
lipoatrophy.  A total of 108 patients with limb
fat less than 20% of limb tissue or limb fat
percentage at least 10% less than
truncal fat percentage by DEXA were
enrolled.  Participants had to have been
receiving combination antiretroviral therapy
unchanged for 12 weeks.  Almost all (98%)
of the subjects were male and white. There
w re a disproportionate number of partici-
pants receiving d4T in the rosiglitazone arm
compared to the control arm (53% versus
29%). All subjects were randomized to 8
mg/day of rosiglitazone or matching placebo
for 48 weeks.  At week 48, there was no dif-
f rence between the study arms in the
change of fat as measured by DEXA.  Limb
fat increased by 0.14 kg (5%) in the rosigli-
tazone group but also increased 0.18 kg
(7%) in the placebo group (mean difference
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“In addition to lipid and 
glucose disorders, 
body shape changes accom-
panying antiretroviral therapy
are a challenge to patients 
and their clinicians.”
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Dear Correctional Colleagues:
In February of this year, over 3,000 of the world’s leading HIV researchers and clinicians
gathered in San Francisco for the Eleventh Annual Conference on Retroviruses and
Opportunistic Infections (CROI).  During this five-day meeting, over 1,000 abstracts were
presented detailing the current state-of-the-art in HIV care. HEPP Report was well repre-
sented, contributing original research to the scientific meeting in both poster and oral for-
mats.  This month, in episode one of our biased review, Dr. David Wohl reports on various
studies conducted on the metabolic complications of antiretroviral therapy (ART).  As high-
ly effective ART prolongs the lives of our HIV-infected patients, many of them are experi-
encing diabetes, lipodystrophy, cholesterol alterations, and other metabolic abnormalities.
Teasing out the contribution of treatment, HIV infection, and other etiologies is a complex
issue that has great significance for the overall well-being of our patients.  
Also this month, Dr. Bethany Weaver presents a case study that highlights some of the
challenging pharmacokinetic interactions that can be seen when patients are receiving
both ART and treatment for opportunistic infections (OIs). This case reminds us that to be
an effective HIV clinician, we must always consider the potential for drug-drug interactions
whenever we alter the treatment regimen of our patients.
This month’s HIV 101 is a two-part table that presents the current recommendations for
when to initiate ART and provides helpful information that can be used to assist patients in
the decision process concerning when to initiate therapy based upon the risk for progres-
sion to OIs.   
Next month, in addition to our continued coverage of CROI, HEPP Report will focus on
some of the most common gastrointestinal manifestations of HIV disease. Thank you for
your ongoing readership, and we encourage your feedback on how we can be most useful
to you in your correctional health care practices.   
Sincerely,
Joseph Bick, MD
Letter from the Editor
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4-0.04 kg [95%CI -0.29 to 0.21]; p=0.74).  CT
scanning of the abdomen and thigh demon-
strated similar decreases in intrabdominal
fat in both groups but neither had an
increase in thigh subcutaneous fat.
Subjects in both study groups reported simi-
lar subjective improvements in lipoatrophy.
Mean insulin levels, which were in the nor-
mal range at baseline, declined equally in
both study arms.  
A curious finding in this trial was the relative
increase in limb fat in the control subjects.
Previous data on the natural history of lipoa-
trophy, much of it from Australia, indicated
that continued worsening of fat wasting
could generally be expected in the absence
of NRTI therapy modification.  One potential
explanation for the improvement seen in the
placebo arm is that many of the patients in
this study had in the months prior to study
entry (before the 12 weeks of stable HAART
required prior to enrollment) switched from
d4T to abacavir.  Abacavir use was high in
both arms at entry.  Despite these concerns,
whether anyone will bother to study this or
like agents for lipoatrophy is unlikely.
The metabolic effects of the extended
release once a day formulation of d4T (d4T-
XR) in comparison to standard d4T (also
called immediate release, or d4T-IR) was
described by investigators from Bristol
Myers Squibb who performed an analysis
using data from two completed clinical trials
comparing d4T-XR and d4T-IR. Over 800
treatment naïve subjects participating in the
trials were studied.  All received d4T-XR or
d4T-IR plus 3TC+EFV. Risk factors for
investigator-defined lipoatrophy were base-
line triglyceride levels >200 mg/dL and age
>40 years. Further, report of lipoatrophy dur-
ing the 48-week studies was almost two
times more likely among d4T-IR assigned
subjects compared to those assigned d4T-
XR.  The combination of these three factors
(high triglycerides, age 40+ and d4T-IR)
seemed to have, at least, an additive effect.
The report states that among subgroups
with different risk factors such as <40 years
of age with triglycerides <200 mg/dL, age
>40 years and triglycerides >200 mg/dL,
etc., the risk of lipoatrophy was greater with
d4T-IR than d4T-XR in each stratum.
Whether these differences were statistically
significant is not stated. There will need to
be additional evidence to indicate the
extended release formulation of d4T is safer
vis-à-vis metabolic toxicity than standard
d4T. A comparison with competitive nucleo-
sides such as ZDV or tenofovir and objective
evaluations of body shape will need to be
produced before the image of d4T can be
rehabilitated.
The effect of the new kid on the formulary,
FTC (Emtriva), on body shape was detailed
in a head-to-head study comparing d4T
(standard formulation) + ddI + EFV versus
FTC + ddI + EFV.  In a placebo-controlled
study of 571 subjects randomized to each
regimen, body shape measurements but no
DEXA or CT scanning were performed at
regular intervals. Subjects in both study
arms gained weight initially but, as has been
seen in other studies, the d4T receiving sub-
jects experienced a later decline in weight.
By week 72 of the study there was a signifi-
cant decline in weight from baseline in the
d4T arm versus a net gain in the FTC arm.
Waist, hip and chest circumference and
abdominal girth were significantly lower in
the d4T group but waist to hip ratio was no
different between study arms.  Investigator-
reported lipodystrophy was more common in
those randomized to d4T group.  Fasting
triglycerides increased in both arms but the
increase was significantly greater in the d4T
arm (+27 mg/dL for FTC, +97.8 mg/dL for
d4T, p <.001). HDL cholesterol also
increased in both groups but more so with
FTC (+13.5 mg/dL) versus d4T (+8.8 mg/dL)
(p=.001). There was no difference between
study arms in the magnitude of the increase
in LDL cholesterol (+15-17 mg/dL), total cho-
lesterol (+37-44 mg/dL) or glucose (+2.5-4.5
mg/dL). As has been reported previously,
FTC performed better virologically.
Lastly, data were also presented on the
effect of T-20 (Fuzeon) on body shape. In an
analysis of body shape data from over 1,000
patients participating in clinical studies of T-
20, there was no evidence of T-20 induced
body shape change.  
Next Month:Part Two of HEPP's Update
from the 11th Conference On Retroviruses
and Opportunistic Infections
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*Nothing to disclose
**Speaker's Bureau: GlaxoSmithKline,
Gilead, Merck, Roche, Abbott
Research Support:  Roche
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Case presentation and discussion by Bethany Weaver*, D.O., M.P.H., Acting Instructor of Medicine, University of Washington Center for AIDS & STD
Research (CFAR) and Northwest Correctional Medicine Education Program. 
Case Study: Drug-drug Interactions Associated with the Use of Antiretroviral Therapy
CASE: A 30 year-old male inmate with class B3 HIV/AIDS and a history of injection drug use, idiopathic thrombocytopenic purpura (ITP),
upper gastrointestinal bleeding, and chronic untreated hepatitis C presents to you for an initial evaluation one week after being transferred
from another facility.  His HIV infection is being treated with Combivir (300 mg AZT plus 150 mg Lamivudine (3TC)) one po bid and
Viramune (Nevirapine) 200 mg po bid. He reports that he has had no problems with this regimen, and has missed only one dose in the
prior six weeks.  His last CD4 count three months ago was 228 (15%) with an HIV-1 viral load by bDNA of <75 copies/ml.  Prior to initia-
tion of antiretroviral therapy (ART) 18 months ago, his nadir CD4 count was 90 (8%) and his highest documented viral load was 35,000
copies/ml.  
The patient's physical exam is unremarkable except for poor venous access. The review of systems is negative except for a history of
low-grade fever and mild non-productive cough.  The patient specifically denies dyspnea, sweats, pain, headache, rash, nausea, vomit-
ing, and change in appetite or weight.  You learn that the patient has traveled throughout the United States over the past three years as a
"roadie" for rock groups.  He specifically denies known exposure to tuberculosis. 
You find in the medical record that a chest radiograph (CXR) obtained during intake screening at his prior facility three weeks ago was
reported to show bilateral infiltrates.  Because of a concern that the patient might have tuberculosis, you immediately have the patient don
a mask while you arrange for his transfer to a negative pressure respiratory isolation room.  
Continued on page 5
5Q: What are likely causes of this patient's current presenta-
tion? 
Once isolated, the patient is subjected to a battery of tests that
includes sputum induction for AFB, bacteria, and pneumocystis
(PCP); a complete blood count (CBC), chemistry panel, blood cul-
tures, and arterial blood gas (ABG); and placement of a tuberculin
skin test. A repeat CXR again demonstrated bilateral upper lobe
infiltrates. Baseline CBC and chemistry panel were unremarkable,
as was his ABG. He was treated empirically with PCP doses of
trimethoprim-sulfamethaxaxole, and azithromycin for community
acquired bacterial pneumonia.  
His PPD skin test was negative at 48 and 72 hours. After five days
of treatment, his sputum specimens were reported as negative for
AFB and PCP. Bacterial culture yielded normal oral flora.  He con-
tinued to have a non-productive cough and daily fevers to 102° F,
while his clinical examination was unchanged.  
Q: What do you do now?
You choose to obtain a CT chest that shows diffuse bilateral non-
calcified pulmonary nodules that appear inflammatory.
Coccidioidomycosis serology and urine histoplasma antigen are
negative.  Bacterial and fungal blood cultures are negative.  The
patient has a bronchoscopy with bronchoalveolar lavage, which
reveals coccidioidomycosis on fungal exam and culture.  
Q: What do you treat your patient with?
You choose to treat him with itraconazole 200 mg po bid instead of
amphotericin.  After eight days of treatment, your patient has failed
to significantly improve. The medical record documents that the
patient has received every dose. He denies emesis or diarrhea.
After 10 days of treatment, you obtain a serum itraconazole level to
check absorption and the level is zero. You decide to double the
dose of itraconazole to 400 mg po bid.  Over the next five days, the
patient becomes afebrile and improves clinically.  He is discharged
to follow-up with you in clinic. Two weeks later, the patient sees you
in clinic.  He is complaining of headache, nausea and vomiting. He
denies fever and cough.  A CXR is significantly improved over past
films. Because of a concern for meningitis, the patient is sent for a
head CT and a lumbar puncture (LP). Both the CT and the LP were
normal.  A chemistry panel reveals an elevated AST and ALT, 246
and 115, respectively. Due to nausea and vomiting and elevated
liver tests, the itraconazole was held.
Q. Why was the serum level of itraconazole initially unde-
tectable? What later caused the patient to develop nausea,
vomiting, headache and elevated liver function tests?
DISCUSSION:
Coccidioidomycosis is usually treated with amphotericin B (0.5 to
0.7 mg/kg/day iv), ketoconazole (400 mg/day po), fluconazole (400
to 800 mg/day po or iv), or itraconazole (200 mg b.i.d. po). The
more seriously ill the patient, the more likely amphotericin B will be
selected for initial therapy. Subacute or chronic presentations are
more likely to be treated initially with an azole drug. Because your
patient is clinically stable, has a rising CD4 count, and has poor
venous access he was initially treated with itraconazole.  
Nevirapine is an inducer of cytochrome P450 3A4 enzymes, which
are also involved in the metabolism of itraconazole. There is limited
data concerning the co-administration of nevirapine and itracona-
zole. Based upon the known pharmacokinetics of the drugs and
studies showing nevirapine induces the metabolism of ketocona-
zole, the concurrent administration of nevirapine and itraconazole is
generally not recommended. Increasing the dose of itraconazole as
a means to overcome the presumed induced metabolism by nevi-
rapine is an option, but without monitoring drug levels it is difficult in
an individual patient to ensure therapeutic levels while avoiding tox-
icity. This patient initially failed to respond to therapy and was found
to have undetectable serum levels of itraconazole.  Once his dose
of itraconazole was doubled, he clinically improved.  What he failed
to tell you was that he chose to stop his antiretroviral therapy
because another inmate told him that nevirapine can "mess up my
liver." Once nevirapine was discontinued, his serum level of itra-
conazole climbed precipitously leading to signs and symptoms of
toxicity. The patient's chronic liver disease also could have influ-
enced his serum levels. 
When the initial decision was made to treat the patient's coccid-
ioidomycosis infection, there were a number of suitable options.  If
the ART regimen was to remain unchanged, the patient could have
been treated with amphotericin. Amphotericin was probably not
necessary in this patient since his coccidioidomycoses infection
appeared to be isolated to the lungs, he was only mildly ill, and he
had an improving immune system. Fluconazole exhibits less drug-
drug interactions with nevirapine than does itraconazole, ketocona-
zole, or voriconazole. Alternatively, the ART regimen could have
been altered to include agents that are less likely to alter the metab-
olism of itraconazole. 
The treatment of HIV-infected persons has become increasingly
complicated.  Many of the medications used to treat HIV and asso-
ciated conditions can lead to complex pharmacokinetic interactions,
and this should always be kept in mind whenever changes are
made to a patient's medication regimen. Excellent resources are
available which detail many of the most common interactions, and
can be invaluable to clinicians as they attempt to adhere to the dic-
tum primum non nocere. 
DISCLOSURES:
*Stockholder: Pfizer
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docs/mdxhome.html
Smith PF, DiCenzo R, Morse GD. Clinical pharmacokinetics of non-
nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet.
2001;40(12):893-905. Review.
CASE STUDY...(continued from page 4)
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TABLE 1. Helping HIV-Infected Persons Decide When to Start HAART
Modified from the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Recommendations for
When to Initiate Antiretroviral Therapy in Chronic HIV Infection, November 10, 2003.
http://aidsinfo.nih.gov/guidelines/adult/AA_111003.html.
Clinical Category
Symptomatic (AIDS or
severe symptoms)
Asymptomatic, AIDS
Asymptomatic
Asymptomatic
Asymptomatic
CD4+  T-Cell Count
Any value
CD4+  T-cells
<200/mm3
CD4+ T-cells >200/mm3
but <350/mm3
CD4+  T-cells
>350/mm3
CD4+ T-cells 
>350/mm3
Plasma HIV RNA
Any value
Any value
Any value
>55,000 (by RT-PCR or
bDNA)**
<55,000 (by RT-PCR or
bDNA)**
Recommendation
Treat
Treat
Most clinicians recommend offering treat-
ment*
Some clinicians recommend initiating therapy,
as the three-year risk for untreated patients to
develop AIDS is >30%. Other clinicians rec-
ommend deferring therapy and monitoring the
CD4+ T-cell count and plasma HIV RNA more
frequently. Clinical outcome data after initiat-
ing therapy are lacking.
Most clinicians recommend deferring therapy
and monitoring the CD4+ T-cell count, as the
three-year risk for untreated patients to devel-
op AIDS is <15%.
* Clinical benefit has been demonstrated in controlled trials only for patients with CD4+ T-cells <200/mm3
** Although a 2-2.5 fold difference existed between RT-PCR and the first bDNA assay (version 2.0), with the 3.0 version bDNA assay, values
obtained by bDNA and RT-PCR are similar except at the lower end of the linear range (<1,500 copies/mL).
TABLE 2. The Risk for Progression to AIDS-Defining Illness Among a Cohort of Men Not
Receiving HAART, Predicted by Baseline CD4+ T-Cell Count and HIV Viral Load*
bDNA
<500
501-3,000
3,001-10,000
10,001-30,000
>30,000
bDNA
<500
501-3,000
3,001-10,000
10,001-30,000
>30,000
bDNA
<500
501-3,000
3,001-10,000
10,001-30,000
>30,000
RT-PCR
<1,500
1,501-7,000
7,001-20,000
20,001-55,000
>55,000
RT-PCR
<1,500
1,501-7,000
7,001-20,000
20,001-55,000
>55,000
RT-PCR
<1,500
1,501-7,000
7,001-20,000
20,001-55,000
>55,000
n
0§
3§
7
20
70
n
3§
27
44
53
104
n
119
227
342
323
262
3 years
-
-
14.3
50.0
85.5
3 years
-
0
6.9
36.4
64.4
3 years
1.7
2.2
6.8
14.8
39.6
6 years
-
-
28.6
75
97.9
6 years
-
20.0
44.4
72.2
89.3
6 years
5.5
16.4
30.1
51.2
71.8
9 years
-
-
64.3
90.0
100.0
9 years
-
32.2
66.2
84.5
92.9
9 years
12.7
30.0
53.5
73.5
85.0
‡ In the reference study, AIDS was defined according to the 1987 CDC definition, which did not include asymptomatic persons with CD4+ T-cells
counts < 200 cells/mm3. 
§ Too few subjects were in the category to provide a reliable estimate of AIDS risk. 
^ A recent evaluation of data from the (MACS) Multicenter AIDS Cohort Study of 231 persons with CD4+ T-cell counts >200 and <350 cells/mm3
demonstrated that of 40 (17%) persons with plasma HIV RNA <10,000 copies/mL, none progressed to AIDS by 3 years. Of 28 individuals (29%) with
plasma viremia of 10,000 - 20,000 copies/mL, 4% and 11% progressed to AIDS at 2 and 3 years, respectively. Plasma HIV RNA was calculated as
RT-PCR values from measured bDNA values.
CD4 <200 cells/mm3
Plasma Viral Load (copies/mL)†
Percentage with AIDS-defining Illness after 3, 6, 9 years‡
Percentage with AIDS-defining Illness after 3, 6, 9 years‡
Percentage with AIDS-defining Illness after 3, 6, 9 years‡
CD4 201 - 350^ cells/mm3
Plasma Viral Load (copies/mL)†
CD4 >350 cells/mm3
Plasma Viral Load (copies/mL)†
Antiretroviral Update 2004
March 16, 2004
Web Conference
12:30 PM  -  3:30 PM EST
CME and Nursing 
credits available
Visit Albany Medical 
Center's Website
Call: 518.262.4674 
Email: ybarraj@mail.amc.edu 
To register as a site in your area:
www.amc.edu/Patient/hiv/
hivconf/index.htm
National HIV/AIDS Update
Conference
March 27-30, 2004
Hyatt Regency
Miami, FL
Sponsored by amfAR
To register contact Jessica Bush
jessica@fa-events.com
Supporting Networks of HIV
Care Project Regional Intensive 
Training 
April 23-23, 2004 
Jackson, MS
Training program covering case
management/administration;
health care delivery; HIV 
positive persons; HIV test-related
counseling; minorities; 
primary care;  
Call: (800) 861.5640
Fax (202) 232-6750 
Visit: www.hivta.org
NCCHC: Clinical Updates in
Correctional Health Care
May 22-25, 2004
Hyatt Regency - Chicago, IL
The NCCHC and Academy of
Correctional Health Professionals
are calling for abstracts. 
Call: 773.880.1460
Fax: 773.880.2424
Visit: www.ncchc.org
9th Northeast Correctional
Health Care Conference
May 26, 2004
Sturbridge Host Hotel
Sturbridge, MA
Contact: Pharmaceutical
Strategies, Inc.
Call: 781.279.2254
Fax: 781.279.2977
Visit:rduhaime@icg-ps.com
Save the 
Dates
7
Study: Accelerated Progression of HCV in
HIV-Infected Persons
A new study reported on 914 HCV/HIV co-
infected patients with elevated serum alanine
aminotransferase (ALT) levels who underwent
liver biopsy in 10 European health care centers
between 1992 and 2002. Researchers found
that HCV/HIV co-infected patients developed
severe liver fibrosis more frequently than did
HCV-mono-infected persons. Nearly one-half
of patients aged >40 years with elevated
serum ALT levels had severe liver fibrosis
(METAVIR score F3 or F4). The authors rec-
ommended that because liver fibrosis wors-
ened rapidly with age, anti-HCV treatment
should be considered as a priority for co-infect-
ed patients, and in the absence of contraindi-
cations, it should be provided as early as pos-
sible. Given the magnitude of the problem
worldwide, strategies aimed at preventing HCV
exposure and reducing alcohol consumption
are warranted, especially in those with HIV
infection.
Martin-Carbonero L et al. Incidence and
Predictors of Severe Liver Fibrosis in HIV-
infected Patients with Chronic Hepatitis C: A
European Collaborative Study. Clin Inf Dis
2004; 38:128-133
ACTG 384:  What is the Optimal Initial
HAART Regimen? 
This large, multicenter study compared six dif-
ferent initial treatment strategies in an attempt
to determine the optimal initial therapy for HIV
and whether some initial regimens increase the
likelihood of treatment success with future regi-
mens. Regimens evaluated included: d4T + ddI
+ efavirenz, d4T + ddI + nelfinavir, AZT + 3TC
+ efavirenz, AZT + 3TC + nelfinavir, d4T + ddI
+ efavirenz + nelfinavir, and AZT + 3TC +
efavirenz + nelfinavir. In this study, the regimen
of AZT + 3TC + efavirenz emerged as clearly
superior to the other five combinations. Data
suggested that the NRTI combination of d4T +
ddI should be avoided as part of initial therapy
because of an increased rate of toxicity. A
metabolic substudy of ACTG 384 also showed
that d4T + ddI leads to a greater degree of fat
atrophy as compared to AZT + 3TC.  The
study also demonstrated that the initial anti-
retroviral regimen is the patient's best chance
for treatment success. 
Sax, P;  AIDS Clinical Care, January 2004
FDA Approves Pegasys Prefilled Syringes
for the Treatment of Hepatitis C
Pegasys, a pegylated alpha interferon, and
Copegus (ribavirin, USP) were approved by
the FDA in December 2002 for use in combi-
nation for the treatment of adults with chronic
hepatitis C who have compensated liver dis-
ease and have not previously been treated
with interferon alpha. Pegasys, which is cur-
rently available in vials as a pre-mixed solution,
is now available in prefilled syringes. Dr. David
Bernstein, Director of Hepatology at North
Shore University Hospital, notes that taking a
medication by self-injection can often be chal-
lenging. "Reducing the number of steps
involved can make the process less intimidat-
ing for patients and reduce the risk of errors."
www.natap.org
Risk Factors And Hepatoxicity Associated
With Nevirapine (Viramune)
The FDA recently revised the Viramune
Product Insert to include a more gender-
focused description of hepatic adverse events
associated with Viramune. The revised section
now indicates that increased AST or ALT levels
and/or co-infection section with hepatitis B or C
at he start of antiretroviral therapy are associ-
ated with a greater risk of hepatic adverse
ev nts. Women appear to have a three-fold
higher risk than men for rash-associated
hepatic events (4.6% versus 1.5%). Patients
with higher CD4 counts may also be at higher
risk for rash-associated hepatic events with
Viramune. In a retrospective review, women
with CD4 counts >250 cells/mm3 had a 9-fold
higher risk of rash-associated hepatic adverse
events compared to women with CD4 counts
<250 cells/mm3 (8.4% versus 0.9%). An
increased risk was observed in men with CD4
counts >400 cells/mm3 (4.5% versus 0.7% for
men with CD4 counts <400 cells/mm3).
www.natap.org
Inside News
Resources
11th Conference on Retroviruses and Opportunistic Infections Program
http://www.retroconference.org/2004/pages/++frame/ProgGlance.htm
CDC Division of HIV/AIDS Prevention
http://www.cdc.gov/hiv/pubs/guidelines.htm 
HCV and HCV/HIV Coinfection Information
http://www.hivandhepatitis.com/reports/2003list.html
http://www.harmreduction.org 
http://www.cdc.gov/ncidod/diseases/hepatitis/c/ 
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through September 30, 2004. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. A microbicide that would be useful in the worldwide efforts to
decrease HIV transmission would have the following characteris-
tics:
a) Be active against a wide range of HIV isolates
b) Retain activity when exposed to body fluids
c) Be inexpensive, easy to manufacture, and stable in a 
variety of climates 
d) Be available without prescription
e) All of the above    
2. A 25-year-old asymptomatic HIV-infected man has a CD4+ cell
count of 370/mm3 and a plasma HIV RNA of 48,000. Most physi-
cians would recommend:
a) Initiating highly antiretroviral therapy with a protease 
inhibitor and two nucleoside agents
b) Initiating highly antiretroviral therapy with a non-
nucleoside reverse transcriptase inhibitor and two nucleoside
reverse transcriptase inhibitors
c) Deferring therapy and following lab work
d) Initiating antiretroviral therapy until the HIV viral load is 
undetectable, and then commencing a "strategic treatment 
interruption"
3. An analysis of data from the Multicenter AIDS Cohort Study
(MACS) suggests that HAART is associated with an increased
risk of diabetes in men. 
a) True
b) False
4. The fact that lipid abnormalities are becoming a frequent com-
plication of HIV therapy is evidenced by the following:
a) The increase in the use of atazanavir
b) The increase in the use of statins and fibrates
c) Problems associated with antiretroviral adherence due to 
disfiguring body shape changes
d) All of the above
5. To date, the only intervention shown to improve peripheral
lipoatrophy to any significant degree has been:
a) The addition of rosiglitazone 
b) Changing to a high fat diet
c) Switching to a regimen that does not include 
stavudine (d4T)
d) Switching to a non-protease inhibitor regimen
6. A recent study from Australia has shown that rosiglitazone is
effective in reversing fat wasting in HIV-associated lipodistrophy
a) True
b) False
BROWN MEDICAL SCHOOL •  OFFICE OF CONTINUING MEDICAL EDUCATION •  BOX G-A2  •  PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME)to provide continuing medical 
education activities for physicians.  
The use of the Brown Medical School name implies review of the educational format and material only.  The opinions, recommendations 
and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the 
Brown Medical School.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or 
register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
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HEPP Report Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1      
Inside News 5  4  3  2  1   5  4  3  2  1
Save the 
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP Report helps you in your work?
Why or why not?
3. What future topics should HEPP Report address?
4. How can HEPPReport be made more useful to you?
5. Do you have specific comments on this issue?
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